The frequency of nasal adverse events was greater in the davunetide group than in the placebo group ( epistaxis 18 [ 12 % ] of 156 vs 13 [ 8 % ] of 156 , rhinorrhoea 15 [ 10 % ] vs eight [ 5 % ] , and nasal discomfort 15 [ 10 % ] vs one [ < 1 % ] ) .